Celularity Statistics
Share Statistics
Celularity has 3.29B shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 3.29B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | -% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -0.22 and the forward PE ratio is null.
| PE Ratio | -0.22 |
| Forward PE | null |
| PS Ratio | 1.93 |
| Forward PS | null |
| PB Ratio | 1.07 |
| P/FCF Ratio | -1.03 |
| PEG Ratio | n/a |
Enterprise Valuation
Celularity Inc. has an Enterprise Value (EV) of 232.10M.
| EV / Earnings | -1.18 |
| EV / Sales | 10.19 |
| EV / EBITDA | -1.26 |
| EV / EBIT | -1.21 |
| EV / FCF | -5.43 |
Financial Position
The company has a current ratio of 0.29, with a Debt / Equity ratio of 0.96.
| Current Ratio | 0.29 |
| Quick Ratio | 0.21 |
| Debt / Equity | 0.96 |
| Total Debt / Capitalization | 48.93 |
| Cash Flow / Debt | -0.99 |
| Interest Coverage | -63.78 |
Financial Efficiency
Return on equity (ROE) is -4.79% and return on capital (ROIC) is -180.77%.
| Return on Equity (ROE) | -4.79% |
| Return on Assets (ROA) | -1.36% |
| Return on Capital (ROIC) | -180.77% |
| Revenue Per Employee | 189.76K |
| Profits Per Employee | -1.64M |
| Employee Count | 120 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 2.78 |
Taxes
| Income Tax | 10.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.51, so Celularity 's price volatility has been higher than the market average.
| Beta | 0.51 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 44.24 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Celularity had revenue of $22.77M and earned -$196.29M in profits. Earnings per share was $-11.02.
| Revenue | 22.77M |
| Gross Profit | 6.75M |
| Operating Income | -192.29M |
| Net Income | -196.29M |
| EBITDA | -183.95M |
| EBIT | -192.29M |
| Earnings Per Share (EPS) | -11.02 |
Balance Sheet
The company has $227.00K in cash and $65.42M in debt, giving a net cash position of -$65.19M.
| Cash & Cash Equivalents | 227.00K |
| Total Debt | 65.42M |
| Net Cash | -65.19M |
| Retained Earnings | -841.79M |
| Total Assets | 128.84M |
| Working Capital | -61.67M |
Cash Flow
In the last 12 months, operating cash flow was -$38.69M and capital expenditures -$4.05M, giving a free cash flow of -$42.73M.
| Operating Cash Flow | -38.69M |
| Capital Expenditures | -4.05M |
| Free Cash Flow | -42.73M |
| FCF Per Share | -2.4 |
Margins
Gross margin is 29.66%, with operating and profit margins of -844.44% and -862.04%.
| Gross Margin | 29.66% |
| Operating Margin | -844.44% |
| Pretax Margin | -862% |
| Profit Margin | -862.04% |
| EBITDA Margin | -807.81% |
| EBIT Margin | -844.44% |
| FCF Margin | -187.66% |
Dividends & Yields
CELUW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for CELUW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -10.38 |
| Piotroski F-Score | 4 |